Questionable relevance of γδ T lymphocytes in renal cell carcinoma

Journal of Immunology

Volumn 180, Issue 5, 2008, Pages 3578-3584

  Inman, Brant A ^a   Frigola, Xavier ^a   Harris, Kimberley J ^a   Kuntz, Susan M ^a   Lohse, Christine M ^a   Leibovich, Bradley C ^a   Kwon, Eugene D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CANCER VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CELL LEVEL; CLEAR CELL CARCINOMA; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MALE; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE; TUMOR NECROSIS; TUMOR VOLUME; ADOPTIVE IMMUNOTHERAPY; BIOSYNTHESIS; CELL CLONE; CELL MOTION; IMMUNOLOGY; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION; TUMOR ASSOCIATED LEUKOCYTE;

AGED; ANTIGENS, CD3; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL MOVEMENT; CLONE CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS;

EID: 49149110966     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.5.3578     Document Type: Article

References (24)

1. Rosenberg, S. A., M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, S. E. Ettinghausen, Y. L. Matory, J. M. Skibber, E. Shiloni, and J. T. Vetto. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313: 1485-1492.
2. Kirkwood, J. M., J. E. Harris, R. Vera, S. Sandler, D. S. Fischer, J. Khandekar, M. S. Ernstoff, L. Gordon, R. Lutes, and P. Bonomi. 1985. A randomized study of low and high doses of leukocyte α-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 45: 863-871.
3. Rosenberg, S. A., J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J. Am. Med. Assoc. 271: 907-913.
4. Viey, E., C. Laplace, and B. Escudier. 2005. Peripheral γδ T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 5: 973-986.
5. Bennouna, J., J. Medioni, F. Rolland, J. L. Misset, M. Campone, H. Sicard, J. Tiollier, F. Romagne, J. Y. Douillard, and F. Calvo. 2005. Phase I clinical trial of bromohydrin pyrophosphate, BrHPP (Phosphatim), a Vy9Vd2 T lymphocyte agonist in combination with low dose interleukin-2 in patients with solid tumors. J. Clin. Oncol. 23: 2536.
6. Bompas, E., E. M. Neidhardt, F. Rolland, I. Philip, C. Galea, S. Salot, J. Tiollier, S. Saiagh, S. Negrier, and J. Bennouna. 2006. An autologous Vy9Vd2 T lymphocyte cell therapy product generated by BrHPP (INNACELL γδ [IGD]) in metastatic renal cell carcinoma patients: phase I clinical trial results. J. Clin. Oncol. 24: 2550.
7. Viey, E., G. Fromont, B. Escudier, Y. Morel, S. Da Rocha, S. Chouaib, and A. Caignard. 2005. Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma. J. Immunol. 174: 1338-1347.
8. Kobayashi, H., Y. Tanaka, J. Yagi, H. Toma, and T. Uchiyama. 2001. γδT cells provide innate immunity against renal cell carcinoma. Cancer Immunol. Immunother. 50: 115-124.
9. Choudhary, A., F. Davodeau, A. Moreau, M. A. Peyrat, M. Bonneville, and F. Jotereau. 1995. Selective lysis of autologous tumor cells by recurrent γδ tumor-infiltrating lymphocytes from renal carcinoma. J. Immunol. 154: 3932-3940.
10. Kowalczyk, D., W. Skorupski, Z. Kwias, and J. Nowak. 1996. Activated γδ T lymphocytes infiltrating renal cell carcinoma. Immunol. Lett. 53: 15-18.
11. Lohse, C. M., and J. C. Cheville. 2005. A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin. Lab. Med. 25: 433-464.
12. Olofsson, K., S. Hellstrom, and M. L. Hammarstrom. 1998. The surface epithelium of recurrent infected palatine tonsils is rich in γδ T cells. Clin. Exp. Immunol. 111: 36-47.
13. Storkel, S., J. N. Eble, K. Adlakha, M. Amin, M. L. Blute, D. G. Bostwick, M. Darson, B. Delahunt, and K. Iczkowski. 1997. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 987-989.
14. Lohse, C. M., M. L. Blute, H. Zincke, A. L. Weaver, and J. C. Cheville. 2002. Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am. J. Clin. Pathol. 118: 877-886.
15. Sobin, S. H., and C. Wittekind. 2002. TNM Classification of Malignant Tumours. Wiley-Liss, New York.
16. Frank, I., M. L. Blute, J. C. Cheville, C. M. Lohse, A. L. Weaver, and H. Zincke. 2002. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: the SSIGN score. J. Urol. 168: 2395-2400.
17. Donner, A., and N. Klar. 1996. The statistical analysis of κ statistics in multiple samples. J. Clin. Epidemiol. 49: 1053-1058.
18. Peyrat, M. A., F. Davodeau, I. Houde, F. Romagne, A. Necker, C. Leget, J. P. Cervoni, N. Cerf-Bensussan, H. Vie, M. Bonneville, et al. 1995. Repertoire analysis of human peripheral blood lymphocytes using a human Vδ3 region-specific monoclonal antibody: characterization of dual T cell receptor (TCR) δ-chain expressors and αβ T cells expressing Vδ3JαCα-encoded TCR chains. J. Immunol. 155: 3060-3067.
19. Borst, J., J. J. van Dongen, R. L. Bolhuis, P. J. Peters, D. A. Hafler, E. de Vries, and R. J. van de Griend. 1988. Distinct molecular forms of human T cell receptor γδ detected on viable T cells by a monoclonal antibody. J. Exp. Med. 167: 1625-1644.
20. Carding, S. R., and P. J. Egan. 2002. γδ T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2: 336-345.
21. McShane, L. M., D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, and G. M. Clark. 2005. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl. Cancer Inst. 97: 1180-1184.
22. Asarnow, D. M., T. Goodman, L. LeFrancois, and J. P. Allison. 1989. Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells. Nature 341: 60-62.
23. Bluestone, J. A., R. Khattri, R. Sciammas, and A. I. Sperling. 1995. TCR γδ cells: a specialized T-cell subset in the immune system. Annu. Rev. Cell. Dev. Biol. 11: 307-353.
24. Hayday, A., and R. Tigelaar. 2003. Immunoregulation in the tissues by γδ T cells. Nat. Rev. Immunol. 3: 233-242.